Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies
Science Advances · 12.06.2026 · 12 (24)
DOI: 10.1126/sciadv.adv2687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 12.06.2026. Verfasst von Hoang Anh T Phan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Nanoparticles, Histocompatibility Antigens Class I, CD8-Positive T-Lymphocytes, High-Throughput Screening Assays. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences.
Abstract (Originalsprache)
MHC-I proteins present epitopic peptides to CD8 + T cells to elicit multifaceted adaptive immune responses. The affinity and avidity of interactions between peptide-MHC molecules and their cognate T cell receptors (TCRs) are fundamental parameters that contribute to the induction of activated or anergic T cell states. Here, we present a multivalent, loadable platform, VLP-Open HLA, featuring a virus-like particle (VLP) which can display up to 60 peptide/HLA [human leukocyte antigen (HLA)] molecules. VLP-Open HLA can be used to stain antigen-specific CD8 + T cells, providing a screening tool for orphan TCRs. When combined with costimulation, VLP-Open HLA acts as an artificial antigen-presenting platform to induce antigen-specific T cell activation and expansion, providing a facile alternative to autologous antigen-presenting cells. Our platform can be adapted to encompass multiple HLA allotypes and costimulatory molecules as mosaic nanoparticles, enabling a range of applications in experimental immunology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Cancer Biology Graduate Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
ORCID-Profile: Hoang Anh T Phan, Soomin Eom, Daniel Hwang, Michael C Young, Shirley M Sun, Molly C Erdman, Yi Sun, Photis Rotsides, Mark M Painter, E John Wherry, Dimitri S Monos, Nikolaos G Sgourakis
Förderung
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases
- Cancer Research UK
- Children's Hospital of Philadelphia
- NIAID
Zitieren
APA
Phan, H. A. T., Eom, S., Hwang, D., Young, M. C., Sun, S. M., Erdman, M. C., Sun, Y., Mallik, L., Rotsides, P., Painter, M. M., Wherry, E. J., Monos, D. S., & Sgourakis, N. G. (2026). Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies. Science Advances, 12(24). https://doi.org/10.1126/sciadv.adv2687
Vancouver
Phan HAT, Eom S, Hwang D, Young MC, Sun SM, Erdman MC, et al. Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies. Science Advances. 2026;12(24). doi:10.1126/sciadv.adv2687
BibTeX
@article{Phan2026,
author = {Phan, Hoang Anh T and Eom, Soomin and Hwang, Daniel and Young, Michael C and Sun, Shirley M and Erdman, Molly C and Sun, Yi and Mallik, Leena and Rotsides, Photis and Painter, Mark M and Wherry, E John and Monos, Dimitri S and Sgourakis, Nikolaos G},
title = {Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {24},
doi = {10.1126/sciadv.adv2687}
}
EUVIMED